outlook pictur
report anoth strong beat rais quarter
remain prefer larg cap name despit
frustrat stock perform dont see reason
name disproportion
outlook within lot pictur
full note detail includ line
perform product-specif updat
ultomiri launch pnh track well
 soliri patient convert
enrol onesourc compani guid
convers ahead schedul
ultomiri recent approv europ launch
germani expect similar adopt curv
soliri growth mg remain robust
patient treatment nmo launch start
number case onesourc first patient
treat headwind launch
due sticki therapi still
look like underappreci opportun given
modest consensu estim peak
high unmet need soliri revenu
impact relat judici order
price canada expect headwind/q go
forward expect spill countri
limit exposur drug price reform price
narrow global band
model updat modest increas outer year
estim net effect pt
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
name rel clean earn growth stori
come year ultomiri switch rapid
continu deliv strong revenu growth franchis
competitor still year away market yet
meaning differenti safeti concern may limit switch
given trajectori franchis mostli shift
ultomiri time biosimilar launch
drug price rhetor limit read-through
modest medicar exposur narrow global price band
limit
intern price indic
mg launch continu strong upsid nmo
soliri launch mg strong nmo opportun
underappreci soliri result show dramat benefit could
enabl blockbust potenti complement could
import role set
like remain range-bound
competit landscap steep alxn indic competitor
emerg potenti compel profil rarx mg
roche/viela nmo apls/regn/roch pnh could price lower
vs amgn biosimilar advanc longev soliri
european ip open question
premium price may limit adopt ex-u countri
premium price soliris/ultomiri may limit access ex-u territori
compani launch new indic even orphan drug price
may come polit scrutiny/attack
soliri unlik move beyond ultra-refractori mg
sever mg patient alreadi start soliri
opportun nmo roche/viela bio alxn heel
build promis pipelin
enough pipelin yet
assembl pipelin partnership
differenti vs current standard care fcrn antibodi
waiha gmg look promis al amyloidosi could
wilson
still long way go investor enough confid
asset includ model/valu carri either
develop competit risk still year market
soliris/ultomiri franchis grow big diversif
remain on-going struggl
submit
initi first human studi
favor impact
million order ahead
unfavor impact
order time relat juli
favor impact
holiday tender
gmg continu
favor impact
tender offer
contribut gmg
continu grow
sale
convers april
relat judici order
soliri price canada
order time ahead
order time ahead
juli convers
jul
includ order
unfavor impact
due order time
growth us germani
continu growth us
includ order
nmo data ye
submit applic earli
sbla submit initi studi
ultomiri
june pdufa initi studi
ultomiri ye
approv nmo june
ye initi studi ultomiri
ye
mg launch track best soliri
launch yet patient treat
jun onesourc
mg launch best soliri launch first
year patient treat end
sept enrol onesourc
mg launch best soliri launch first
year patient treat end dec
patient treat end march
patient soliri mid-april
file submiss pnh
 eu track file japan
on-going studi
children/adolesc pnh
children ahu
on-going studi
children/adolesc pnh
children ahu
ultomiri approv soliri pnh
patient enrol onesourc half
alreadi treat ultomiri
ultomiri approv soliri pnh
patient enrol onesourc
treat april
soliri pnh patient enrol
onesourc treat juli
file
file
submit us
ahu file us
oct pdufa date file approv
eu/japan
initi late
initi late
dose on-going pk studi qw
 data earli
file cta eu
formul initi
initi studi
initi mg studi file
late
initi mg studi earli
initi studi
complet dose studi
initi mg studi nmo studi ye mg dose underway initi nmo
studi ye
plan initi poc studi al
ppm
plan initi poc studi al
ppm
initi poc studi al earli
initi poc studi ppm
initi hsct-tma studi
increas trial size
power superior plan file
trial power superior file
complet enrol earli
waiha pemphigu data
initi waiha anoth
pivot studi
plan initi studi waiha
gmg
issu encout resolv
plan initi studi waiha
gmg late earli
initi studi waiha mg
initi studi
formul earli
announc collabor
announc collabor dicerna announc collabor caelum initi studi initi studi
initi first human studi
announc partnership affibodi
zealand
announc partnership affibodi
zealand
non-gaap
non-gaap sg
margin total
estim soliri ultomiri growth go forward shown outer year
estim gener consensu compani franchis broadli although
could upsid number compani expans new set mg nmo al
ppm robust chart updat model updat
compar consensu estim optimist alxn potenti nmo consensu
current assum peak sale conserv opportun myasthenia
gravi given emerg competit landscap caution outer year growth base
commentari kol well note mg nmo shift soliri ultomiri annual
price declin soliri dose pnh indic wherea ultomiri
dose across set chart updat model updat
drug price increasingli come focu us show alxn ww total
soliri revenu break medicar part b/d medicaid commerci us ex-u
although compani exposur medicare/medicaid revenu
total lower end
approv decemb us
pnh key focu
convers rate given longer patent life
com ultomiri till vs
soliri us
earn call note
pnh patient us
convert soliri ultomiri
enrol onesourc track well
ahead expect compani
expect convers mid sale
import focu pace
ultomiri adopt eu approv
europ pnh juli
ultomiri launch pnh strong european adopt trend
although switch soliri ultomiri strong extend longev
compani franchis given longer exclus ultomiri price discount soliri enabl access
result compani need grow price dynam addit indic switch
pnh compani price ultomiri discount soliri mainten
ahu mg nmo soliri price higher pnh indic ultomiri
presum discount soliri
price ultomiri enabl broader access although also headwind growth higher-
beyond pnh focus convert addit indic ultomiri pdufa
ahu octob addit underway mg plan set
compani also advanc addit formul ultomiri enabl shorter iv deliveri time
well option ahu tricki indic evolv mix acute/chron use
pnh
time file
sinc approv soliri mg launch
strong earn call
note patient soliri
mid-april
estim address popul
soliri myasthenia gravi base
popul patient us
result could still room grow
launch reach bn franchis
could upsid estim
howev base convers
kol mg patient gener well
manag price soliri remain
import consider broader uptak
addit competit landscap
alxn launch soliri mg strong date consensu estim factor
strong continu ramp although may addit upsid
competit landscap myasthenia gravi steep multipl player emerg complement
mechan includ fcrn inhibitor
notabl rarx present data studi zilucoplan qd peptid inhibitor
compel result rang soliri compani initi studi
importantli rarx note intent price zilucoplan meaning discount soliri
rang may enabl broader uptak less flexibl price given
current phase
studi initi
initi studi
dose disclos iv
iv multipl dose frequenc
data
potenti competit threat soliris/ultomiri mg especi program
price discount
soliri recent approv nmo us provid anoth leg growth
compani franchis consensu estim peak current low view
although import consider market
soliri data nmo demonstr
profound benefit reduc risk
relaps greater benefit vs
debilit natur relaps
patient rapidli switch soliri
still meaning unmet need
nmo patient
us approv therapi except
diagnosi rate nmo improv
avail antibodi
relaps diseas may hesit
switch rituxan/oth therapi
given soliri price nmo
sever patient may gain access
competit threat immin
launch roche/viela expect
near term submit
approv may
differenti soliri price
compar roche/chugai satralizumab inebilizumab data soliri
prevent relaps appear superior key consider given burden
relaps diseas howev cost dose conveni may also import factor
competit landscap roche/viela may abl differenti
iv soliri week
subcu satralizumab week
dose inebilizumab monotheapi pbo
relaps last month relaps
last mo mo prior screen
relaps last year least one
last month
 patient
specifi annual mean number
prior screen
number patient
reduct relaps
number relaps
vs pbo
week vs pbo
patient vs pbo
patient vs pbo
patient vs pbo
soliri arm vs pbo
patient worsen diabil pbo vs
inebilizumab fewer new mri lesion
meningococc infect rate upper
respiratori tract infect soliri vs
pbo patient die soliri arm
similar sae satralizumab pbo
group sae placebo group
similar sae inebilizumab pbo
group inebilizumab vs pbo
death sever attack brain event
given strong benefit seen nmo mg initi two addit poc studi year
ultomiri amytroph later sclerosi al primari progress multipl sclerosi ppm
compani note al trial includ patient random placebo soliri
week primari endpoint look chang al function rate scale
unmet need al substanti appear complement involv
although lack robust understand diseas biolog make high risk/high
also plan initi studi ppm although ocrevu approv price
meaning greater benefit need support ultomiri use
initi poc studi ultomiri al earli also plan initi trial
competit landscap pnh ahu shown key competitor track includ
roche/chugai regn/alni
current phase
soliri ultomiri
quarterli updat focu
one iv dose qw
also partner
qw qm
present
pegasu data
unclear studi pt first
post
phase combo soliri
end meet
studi
on-going readout
iv dose follow
competit landscap key upcom catalyst year result inhibitor
twice weekli infus expect decemb pegasu head head studi compar soliri
patient continu anemia soliri
theori inhibit could address extravascular hemolysi addit intravascular hemolysi
inhibit treat howev safeti risk could amplifi well given central role
play complement pathway still tbd risk hypothet deliveri profil
especi vs qw ultomiri avail could limit adopt sever patient see
thought data present far
also initi princ studi come month head head studi vs soliri nave
import upcom read-out pegasu studi result expect decemb
patient treat soliri continu transfus depend could candid
switch addit patient remain sever anem
howev indic patient may clinic evid extravascular
hemolysi could benefit inhibitor although studi small number patient
note mediat extravascular hemolysi clinic evid
patient treat soliri
european ip soliri remain question earlier year epo revok formul patent
set expir
appeal decis could take addit year
also oral hear composit matter/pnh method use patent
septemb could extend ip protect
us file ipr alxn patent expir includ
composit matter method use formul patent updat may avail later
year well
term biosimilar updat biosimilar soliri launch russia last quarter note
specif russia/kazakhstan limit read-through territori
unclear data gener support approval/launch note
repres small percent soliri revenu
amgn biosimilar studi abp enrol patient estim
enrol year studi year primari endpoint earliest abp could
avail like
biosimilar updat ip litig soliri remain overhang although rapid
convers ultomiri may help mitig fear
expand pipelin antibodi mediat
autoimmun diseas acquisit
syntimmun compani gain
fcrn inhibitor
earlier year note
manufactur impur correct
delay result studi note
igg lower shown right
fcrn landscap competit
competit landscap need monitor see
argx initi
plan initi studi warm
autoimmun hemolyt anemia waiha earli
also plan initi develop
 version earli
pursu version mg start
studi
invest fcrn franchis
announc partnership develop affibodi
bival antibodi mimet may easili
doubl fcrn effort like mechan landscap
metabol side strensiq deliv annual sale provid
diversif away compani complement franchis
kanuma revenu continu sluggish report sale
follow acquisit wilson therapeut expand wilson diseas
oral copper bind agent studi on-going result expect
design superior vs standard care interest profil although gene therapi approach
advanc includ vivet/pf well need track
alxn metabol franchis continu grow modestli driven increas penetr
strensiq kanuma sale continu underwhelm wilson diseas could provid
inflect franchis
addit program discuss addit pipelin opportun advanc includ
partnership caelum develop compani lead program light chain al
diagnos patient al amyloidosi
demonstr vivo target engag al amyloid
studi initi earli
fail similar program mani suspect antibodi appropri target
al amyloid compani never shown robust target engag
complement pharma partnership develop target antibodi neurolog diseas
lead program bind addit detail potenti target indic avail
futur
announc day bispecif could enabl easier
dose variou indic first human clinic studi initi late
also announc collabor zealand pharma develop addit complement therapi
partner rnai across multipl potenti complement target
bolster pipelin recent extern intern updat
inform inc wkcdi endors data view opinion find express herein
document materi prepar behalf evercor isi employe
average ep beat last quarter
ep beat last quarter
 sale
tax adjust adjust reflect sni jv
 sale
npv
npv fcf-per-share
arget market cap impli pt
arget market cap impli pt
target ev impli pt
growth rate
upsid price
incom tax
pro-forma incom tax
compani report evr isi analyst estim
depreci amort
impair intang asset
chang fv conting consid
premium amort secur
prepaid expens asset
account payabl accru expens liabil
oper
purchas trade secur
purchas invest
purchas pp
invest
payment term loan
repurchas common stock
proce exercis stock/opt
financ
effect exchang rate chang
increas cash/equiv
cash/equiv begin
cash/equiv end
compani report evr isi analyst estim
deriv valuat base dcf use discount rate appli
commerci stage biotech compani termin growth rate reflect optimist outlook durabl
compani franchis includ million product revenu reflect potenti busi
risk price target includ intensifi competit threat formid biopharma compani along potenti
amplifi price pressur failur build compel develop pipelin
articl articl
time dissemin juli
analyst josh schimmer shenston huang neeraj koduri angela ni maneka mirchandaney primarili respons prepar
research report attest follow view opinion render research report reflect person view
subject compani issuer part research analyst compens directli relat specif
recommend view research report
